
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4057376/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cutaneous adverse events of immune checkpoint inhibitor therapy: incidence and types of reactive dermatoses. Journal of Dermatological Treatment, 2022, 33, 1691-1695.	2.2	11
2	Immune-related adverse events and the balancing act of immunotherapy. Nature Communications, 2022, 13, 392.	12.8	125
3	Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, 2022, 40, 1301-1311.	1.6	445
4	Role and impact of immune checkpoint inhibitors in neoadjuvant treatment for NSCLC. Cancer Treatment Reviews, 2022, 104, 102350.	7.7	18
5	Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial. Lung Cancer, 2022, 166, 84-93.	2.0	7
6	Murine fecal microbiota transfer models selectively colonize human microbes and reveal transcriptional programs associated with response to neoadjuvant checkpoint inhibitors. Cancer Immunology, Immunotherapy, 2022, 71, 2405-2420.	4.2	10
7	Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)–related interstitial lung disease/pneumonitis—Focus on proactive monitoring, diagnosis, and management. Cancer Treatment Reviews, 2022, 106, 102378.	7.7	60
8	Cutaneous Toxicities Associated with Immune Checkpoint Inhibitors: An Observational, Pharmacovigilance Study. Journal of Investigative Dermatology, 2022, 142, 2896-2908.e4.	0.7	9
9	Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study. , 2022, 10, e004670.		21
10	An Oncology Urgent Care Clinic for the Management of Immune-Related Adverse Events: A Descriptive Analysis. Current Oncology, 2022, 29, 4342-4353.	2.2	0
11	Durvalumab (durva) after chemoradiotherapy (CRT) in unresectable, stage III, EGFR mutation-positive (EGFRm) NSCLC: A post hoc subgroup analysis from PACIFIC Journal of Clinical Oncology, 2022, 40, 8541-8541.	1.6	11
12	Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. , 2021, 9, e001731.		45
13	A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors. Clinical Cancer Research, 2021, 27, 2571-2583.	7.0	22
14	Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial. Journal of Thoracic Oncology, 2021, 16, 860-867.	1.1	323
15	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. Journal of Thoracic Oncology, 2021, 16, 1030-1041.	1.1	79
16	Immune-Related Adverse Events and Efficacy—The More It Hurts, the Better It Works?—Reply. JAMA Oncology, 2021, 7, 945.	7.1	0
17	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
18	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87

2

#	Article	IF	CITATIONS
19	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature, 2021, 596, 126-132.	27.8	234
20	Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers. , 2021, 9, e002473.		33
21	Radiation Versus Immune Checkpoint Inhibitor Associated Pneumonitis: Distinct Radiologic Morphologies. Oncologist, 2021, 26, e1822-e1832.	3.7	31
22	Real-World Incidence and Management of Immune-Related Adverse Events from Immune Checkpoint Inhibitors: Retrospective Claims-Based Analysis. Cancer Investigation, 2021, 39, 789-796.	1.3	5
23	Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC. JTO Clinical and Research Reports, 2021, 2, 100220.	1.1	4
24	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 3978-3992.	1.6	121
25	Immunotherapy for Stage III NSCLC: Durvalumab and Beyond. Lung Cancer: Targets and Therapy, 2021, Volume 12, 123-131.	2.7	4
26	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 4073-4126.	1.6	580
27	Lung cancer and family-centered concerns. Supportive Care in Cancer, 2020, 28, 497-505.	2.2	2
28	Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nature Cancer, 2020, 1, 99-111.	13.2	141
29	Lower Survival in Patients Who Develop Pneumonitis Following Immunotherapy for Lung Cancer. Clinical Lung Cancer, 2020, 21, e169-e170.	2.6	24
30	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. Journal of Clinical Oncology, 2020, 38, 576-583.	1.6	135
31	A Multidisciplinary Approach for Patients with Preexisting Lung Diseases and Immune Checkpoint Inhibitor Toxicities. Oncologist, 2020, 25, e1589-e1592.	3.7	3
32	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncology, The, 2020, 21, e398-e404.	10.7	74
33	Multidisciplinary Approach to Immune-Mediated Diarrhea and Colitis From Immunotherapy for Cancer. JCO Oncology Practice, 2020, 16, 462-463.	2.9	2
34	Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non–Small Cell Lung Cancer. JAMA Oncology, 2020, 6, 1952.	7.1	241
35	Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer. Lung Cancer, 2020, 150, 249-251.	2.0	7
36	Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. , 2020, 8, e001282.		108

#	Article	IF	CITATIONS
37	4401 Incidence, management, and outcomes of immune-related adverse events (irAEs): an analysis of a multidisciplinary toxicity team for cancer immunotherapy related irAEs. Journal of Clinical and Translational Science, 2020, 4, 73-73.	0.6	0
38	Checkpoint Inhibitor Pneumonitis: Mechanisms, Characteristics, Management Strategies, and Beyond. Current Oncology Reports, 2020, 22, 56.	4.0	23
39	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet, The, 2020, 395, 1907-1918.	13.7	1,395
40	Principles of Immunotherapy in Non-Small Cell Lung Cancer. Thoracic Surgery Clinics, 2020, 30, 187-198.	1.0	19
41	Immune-related (IR)-pneumonitis during the COVID-19 pandemic: multidisciplinary recommendations for diagnosis and management. , 2020, 8, e000984.		15
42	Chronic immune checkpoint inhibitor pneumonitis. , 2020, 8, e000840.		55
43	Immune-Related Pneumonitis After Chemoradiotherapy and Subsequent Immune Checkpoint Blockade in Unresectable Stage III Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e435-e444.	2.6	46
44	Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Annals of the Rheumatic Diseases, 2020, 79, 332-338.	0.9	140
45	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 1327-1337.	7.0	90
46	Information Visualization Platform for Postmarket Surveillance Decision Support. Drug Safety, 2020, 43, 905-915.	3.2	6
47	Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. JTO Clinical and Research Reports, 2020, 1, 100074.	1.1	10
48	Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. , 2020, 8, e001675.		9
49	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 230-241.	4.9	284
50	681â€Single pipeline re-analysis revises microbiome associations with anti-tumor response to checkpoint inhibitors. , 2020, , .		0
51	Immune-Related Adverse Events: A Case-Based Approach. Frontiers in Oncology, 2019, 9, 530.	2.8	31
52	Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes. Journal of Oncology Practice, 2019, 15, e825-e834.	2.5	37
53	Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor–related Pneumonitis. An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine, 2019, 200, e31-e43.	5.6	97
54	Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovascular Research, 2019, 115, 854-868.	3.8	311

#	Article	IF	CITATIONS
55	Genome-wide cell-free DNA fragmentation in patients with cancer. Nature, 2019, 570, 385-389.	27.8	764
56	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. Journal of Clinical Oncology, 2019, 37, 2738-2745.	1.6	138
57	Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer, 2019, 20, e470-e479.	2.6	80
58	Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1. , 2019, 7, 40.		42
59	Impact of Checkpoint Inhibitor Pneumonitis on Survival in NSCLC Patients Receiving Immune Checkpoint Immunotherapy. Journal of Thoracic Oncology, 2019, 14, 494-502.	1.1	114
60	Early Noninvasive Detection of Response to Targeted Therapy in Non–Small Cell Lung Cancer. Cancer Research, 2019, 79, 1204-1213.	0.9	75
61	Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer. Cancer Research, 2019, 79, 1214-1225.	0.9	226
62	The alveolar immune cell landscape is dysregulated in checkpoint inhibitor pneumonitis. Journal of Clinical Investigation, 2019, 129, 4305-4315.	8.2	100
63	A Multidisciplinary Toxicity Team for Cancer Immunotherapy–Related Adverse Events. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 712-720.	4.9	71
64	Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 255-289.	4.9	393
65	Successful Treatment of Scar Pain with Scrambler Therapy. Cureus, 2019, 11, e5903.	0.5	4
66	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. New England Journal of Medicine, 2018, 378, 1976-1986.	27.0	1,495
67	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 916-925.	0.8	257
68	Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Seminars in Arthritis and Rheumatism, 2018, 48, 553-557.	3.4	119
69	PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10, S4034-S4037.	1.4	5
70	2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors. Journal of Clinical and Translational Science, 2018, 2, 44-45.	0.6	0
71	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer. Chest, 2018, 154, 1416-1423.	0.8	230
72	Pneumonitis in Non–Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. Journal of Thoracic Oncology, 2018, 13, 1930-1939.	1.1	282

#	Article	IF	CITATIONS
73	Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series. , 2018, 6, 104.		55
74	Rediagnosis of Lung Cancer as NUT Midline Carcinoma Based on Clues From Tumor Genomic Profiling. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 467-472.	4.9	13
75	Preoperative contralateral lung radiation dose is associated with postoperative pulmonary toxicity in patients with locally advanced non-small cell lung cancer treated with trimodality therapy. Practical Radiation Oncology, 2018, 8, e239-e248.	2.1	0
76	Frequency, impact and a preclinical study of novel <i>ERBB</i> gene family mutations in HER2-positive breast cancer. Therapeutic Advances in Medical Oncology, 2018, 10, 175883591877829.	3.2	11
77	Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. Current Treatment Options in Oncology, 2018, 19, 46.	3.0	16
78	The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity. Cancer Immunology Research, 2018, 6, 888-899.	3.4	118
79	An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition. Journal of Clinical Investigation, 2018, 129, 75-77.	8.2	1
80	A multidisciplinary toxicity team for cancer immunotherapy-related adverse events Journal of Clinical Oncology, 2018, 36, 6538-6538.	1.6	9
81	Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint Blockade. Oncologist, 2017, 22, 627-630.	3.7	74
82	Inflammatory arthritis due to immune checkpoint inhibitors: challenges in diagnosis and treatment. Immunotherapy, 2017, 9, 5-8.	2.0	20
83	Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer. Cancer Discovery, 2017, 7, 264-276.	9.4	706
84	Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Annals of the Rheumatic Diseases, 2017, 76, 43-50.	0.9	317
85	Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy. Journal of Clinical Oncology, 2017, 35, 709-717.	1.6	829
86	Reply to M. Nishino et al. Journal of Clinical Oncology, 2017, 35, 1629-1630.	1.6	1
87	Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors. PLoS ONE, 2017, 12, e0182665.	2.5	54
88	The next frontier in non-small cell lung cancer: synergizing radiation therapy and immune checkpoint blockade. Clinical Advances in Hematology and Oncology, 2017, 15, 615-625.	0.3	6
89	Pneumonitis From Anti-PD-1/ PD-L1 Therapy. Oncology, 2017, 31, 739-46, 754.	0.5	23
90	Immuneâ€Related Adverse Events From Immune Checkpoint Inhibitors. Clinical Pharmacology and Therapeutics, 2016, 100, 242-251.	4.7	84

6

#	Article	IF	CITATIONS
91	Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1. Cancer Immunology Research, 2016, 4, 383-389.	3.4	247
92	Immunotherapy for Lung Cancer: No Longer an Abstract Concept. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 771-782.	2.1	12
93	The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. Lung Cancer, 2016, 102, 21-27.	2.0	11
94	Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes. Clinical Lung Cancer, 2016, 17, e121-e129.	2.6	116
95	Adaptive Neoadjuvant Chemotherapy Guided by 18 F-FDG PET in Resectable Non–Small Cell Lung Cancers: The NEOSCAN Trial. Journal of Thoracic Oncology, 2016, 11, 537-544.	1.1	42
96	Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma–like and Non–Small Cell Carcinoma–like Subsets. Clinical Cancer Research, 2016, 22, 3618-3629.	7.0	342
97	KRAS-Mutant Lung Cancers in the Era of Targeted Therapy. Advances in Experimental Medicine and Biology, 2016, 893, 155-178.	1.6	23
98	Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers. PLoS ONE, 2016, 11, e0146063.	2.5	17
99	What does the future hold for immunotherapy in cancer?. Annals of Translational Medicine, 2016, 4, 177-177.	1.7	9
100	The 2014 San Antonio Breast Cancer Symposium: A successful lift-off for breast immunotherapy?. Npj Breast Cancer, 2015, 1, .	5.2	0
101	Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib. Cancer, 2015, 121, 3212-3220.	4.1	160
102	Differences in the survival of patients with recurrent versus de novo metastatic <i>KRAS</i> â€mutant and <i>EGFR</i> â€mutant lung adenocarcinomas. Cancer, 2015, 121, 2078-2082.	4.1	15
103	Emerging immunotherapy strategies in breast cancer. Immunotherapy, 2014, 6, 195-209.	2.0	23
104	Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunology Research, 2014, 2, 127-132.	3.4	122
105	Immune Checkpoint Blockade. Hematology/Oncology Clinics of North America, 2014, 28, 585-600.	2.2	70
106	Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation?. Journal of Thoracic Oncology, 2013, 8, 1215-1221.	1.1	35
107	An Irish breast cancer survivorship study: Are we meeting our patients' needs?. Journal of Clinical Oncology, 2013, 31, e20687-e20687.	1.6	0
108	Should patients with extrapulmonary small cell carcinoma receive prophylactic cranial irradiation? An Irish experience Journal of Clinical Oncology, 2012, 30, 2609-2609.	1.6	3